Russell Investments Group Ltd. Acquires 18,337 Shares of Dynavax Technologies Corporation $DVAX

Russell Investments Group Ltd. boosted its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 770.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,718 shares of the biopharmaceutical company’s stock after acquiring an additional 18,337 shares during the period. Russell Investments Group Ltd.’s holdings in Dynavax Technologies were worth $269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DVAX. Envestnet Asset Management Inc. grew its holdings in Dynavax Technologies by 20.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 2,796 shares in the last quarter. Raymond James Financial Inc. bought a new position in Dynavax Technologies during the 4th quarter worth about $192,000. First Trust Advisors LP bought a new position in Dynavax Technologies during the 4th quarter worth about $847,000. Tower Research Capital LLC TRC grew its holdings in Dynavax Technologies by 11.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,839 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 1,966 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of Dynavax Technologies by 34.5% during the fourth quarter. Hsbc Holdings PLC now owns 18,953 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 4,859 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dynavax Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $24.33.

Dynavax Technologies Stock Down 1.5%

DVAX stock opened at $10.12 on Tuesday. The firm has a 50 day moving average of $10.62 and a 200 day moving average of $11.28. The stock has a market capitalization of $1.19 billion, a PE ratio of -22.00 and a beta of 1.24. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. The company had revenue of $95.44 million during the quarter, compared to analysts’ expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Scott Dunseth Myers bought 3,800 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was bought at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director directly owned 35,004 shares of the company’s stock, valued at approximately $378,743.28. This trade represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.98% of the stock is owned by company insiders.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.